LifeSci Capital Initiates Coverage of Ohr Pharmaceutical

Developing Topical Treatment to Enhance Visual Acuity in Wet AMD; Report Available here: www.lifescicapital.com/equity-research/ohr/

NEW YORK, NY / ACCESSWIRE / July 28, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Ohr Pharmaceutical (NasdaqCM: OHRP), a biotechnology company focused on the development of novel ophthalmologic therapeutics. The Company is currently preparing for a Phase III clinical program with OHR-102, a topical treatment for neovascular age-related macular degeneration (wet AMD). The Phase III program is expected to begin in the second half of 2015 based on encouraging Phase II results suggesting an improvement in visual acuity for patients treated with OHR-102 and Lucentis as compared to Lucentis alone.

Ohr Pharmaceutical is developing the first-ever topical treatment for wet AMD. OHR-102, an eye drop formulation of squalamine lactate, recently completed a Phase II clinical trial. Squalamine inhibits several growth factors to block angiogenesis in the back of the eye. There is potential for new therapies like OHR-102 to act synergistically with VEGF inhibitors, the current standard of care, to further improve visual outcomes. As a topical treatment, OHR-102 has the potential to achieve this goal without requiring additional, inconvenient intraocular injections.

In a 41 page Initiation Report LifeSci Capital explains the clinical data supporting a Phase III program with OHR-102 in wet AMD and the potential market opportunity. The report also discusses Ohr’s sustained release technology and its application in ophthalmology.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Ohr Pharmaceutical as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 430872